MedPath
Found 12 clinical trials|View Analysis
Sort by:

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Phase 3
Recruiting
Conditions
Bronchial Diseases
Interventions
First Posted Date
2024-12-04
Last Posted Date
2025-01-07
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
225
Registration Number
NCT06716606
Locations
🇰🇷

GSK Investigational Site, Yongsan-Ku Seoul, Korea, Republic of

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

Phase 2
Not yet recruiting
Conditions
Systemic Sclerosis Associated Interstitial Lung Disease
Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD)
Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Interventions
Drug: GenSci048
Drug: GenSci048 placebo
First Posted Date
2024-01-03
Last Posted Date
2024-01-03
Lead Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Target Recruit Count
30
Registration Number
NCT06189495
Locations
🇨🇳

Qilu Hospital of Shandong University, Jinan, Shandong, China

🇨🇳

West China Hospital of Sichuan University, Chengdu, Sichuan, China

🇨🇳

Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

and more 1 locations

"Pulmonary Rehabilitation Program in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis"

Recruiting
Conditions
Systemic Sclerosis Associated Interstitial Lung Disease
Interventions
Procedure: Pulmonary Rehabilitation Program
First Posted Date
2023-10-27
Last Posted Date
2024-02-02
Lead Sponsor
Coordinación de Investigación en Salud, Mexico
Target Recruit Count
67
Registration Number
NCT06105073
Locations
🇲🇽

Centro Medico Nacional La Raza, Mexico City, Mexico

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Phase 2
Recruiting
Conditions
Scleroderma, Systemic
Systemic Sclerosis Associated Interstitial Lung Disease
Interventions
Other: Placebo
Biological: Belimumab
First Posted Date
2023-05-26
Last Posted Date
2024-12-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
300
Registration Number
NCT05878717
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Phase 2
Recruiting
Conditions
Idiopathic Pulmonary Fibrosis
Systemic Sclerosis With Lung Involvement
Interventions
Drug: Placebo
Drug: Vixarelimab
First Posted Date
2023-03-27
Last Posted Date
2024-12-17
Lead Sponsor
Genentech, Inc.
Target Recruit Count
320
Registration Number
NCT05785624
Locations
🇲🇽

Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Southern Arizona VA Health Care System NAVREF PPDS, Tucson, Arizona, United States

and more 108 locations

Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease

Recruiting
Conditions
Systemic Sclerosis
Interstitial Lung Disease
First Posted Date
2022-08-01
Last Posted Date
2024-08-27
Lead Sponsor
Central Hospital, Nancy, France
Target Recruit Count
100
Registration Number
NCT05482607
Locations
🇫🇷

Central Hospital, Nancy, France

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

Phase 2
Recruiting
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interstitial Lung Disease
Interventions
Drug: Tulisokibart
Diagnostic Test: Companion diagnostic ( CDx)
Drug: Placebo
First Posted Date
2022-03-08
Last Posted Date
2024-12-24
Lead Sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Target Recruit Count
152
Registration Number
NCT05270668
Locations
🇭🇺

Budai Irgalmasrendi Korhaz ( Site 4252), Budapest, Hungary

🇦🇷

Consultorios Médicos Dr. Doreski ( Site 4800), Caba, Buenos Aires, Argentina

🇦🇷

Instituto Medico de la Fundacion Estudios Clinicos ( Site 4803), Rosario, Santa Fe, Argentina

and more 83 locations

Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease

Withdrawn
Conditions
Interstitial Lung Disease
Systemic Sclerosis
First Posted Date
2022-01-04
Last Posted Date
2024-08-27
Lead Sponsor
Central Hospital, Nancy, France
Registration Number
NCT05177471
Locations
🇫🇷

CHU Nancy, Vandœuvre-lès-Nancy, Grand Est, France

Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease

Phase 3
Conditions
Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)
Interventions
Other: placebo
Drug: Pirfenidone
First Posted Date
2019-02-27
Last Posted Date
2019-02-27
Lead Sponsor
Beijing Continent Pharmaceutical Co, Ltd.
Target Recruit Count
144
Registration Number
NCT03856853
Locations
🇨🇳

Zhang, Ling, Beijing, Beijing, China

A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

Phase 1
Completed
Conditions
Scleroderma, Systemic
Interventions
Drug: Microgynon
Drug: Nintedanib
First Posted Date
2018-09-18
Last Posted Date
2020-11-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
17
Registration Number
NCT03675581
Locations
🇪🇸

Hospital Santa Creu i Sant Pau, Barcelona, Spain

🇪🇸

Hospital Vall d'Hebron, Barcelona, Spain

🇳🇱

Radboud Universitair Medisch Centrum, Nijmegen, Netherlands

and more 7 locations
© Copyright 2025. All Rights Reserved by MedPath